GPC2 CAR T cells
Phase 1Cell therapy
GPC2 CAR T cells is one of 63 biologic programs targeting Retinoblastoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
81 competitors in Medulloblastoma
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Glucophage
EMD SeronoPhase 3
Erivedge
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GPC2 CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SStanford University